Anti-S35G2/ SLC35G2/ ™EM22 monoclonal antibody
Anti-S35G2/ SLC35G2/ ™EM22 antibody for FACS & in-vivo assay
Go to SLC35G2/SLC35G2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-MP1609-Ab-1/ GM-Tg-hg-MP1609-Ab-2 | Anti-Human SLC35G2 monoclonal antibody | Human |
| GM-Tg-rg-MP1609-Ab-1/ GM-Tg-rg-MP1609-Ab-2 | Anti-Rat SLC35G2 monoclonal antibody | Rat |
| GM-Tg-mg-MP1609-Ab-1/ GM-Tg-mg-MP1609-Ab-2 | Anti-Mouse SLC35G2 monoclonal antibody | Mouse |
| GM-Tg-cynog-MP1609-Ab-1/ GM-Tg-cynog-MP1609-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC35G2 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-MP1609-Ab-1/ GM-Tg-felg-MP1609-Ab-2 | Anti-Feline SLC35G2 monoclonal antibody | Feline |
| GM-Tg-cang-MP1609-Ab-1/ GM-Tg-cang-MP1609-Ab-2 | Anti-Canine SLC35G2 monoclonal antibody | Canine |
| GM-Tg-bovg-MP1609-Ab-1/ GM-Tg-bovg-MP1609-Ab-2 | Anti-Bovine SLC35G2 monoclonal antibody | Bovine |
| GM-Tg-equg-MP1609-Ab-1/ GM-Tg-equg-MP1609-Ab-2 | Anti-Equine SLC35G2 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-MP1609-Ab-1/ GM-Tg-hg-MP1609-Ab-2; GM-Tg-rg-MP1609-Ab-1/ GM-Tg-rg-MP1609-Ab-2; GM-Tg-mg-MP1609-Ab-1/ GM-Tg-mg-MP1609-Ab-2; GM-Tg-cynog-MP1609-Ab-1/ GM-Tg-cynog-MP1609-Ab-2; GM-Tg-felg-MP1609-Ab-1/ GM-Tg-felg-MP1609-Ab-2; GM-Tg-cang-MP1609-Ab-1/ GM-Tg-cang-MP1609-Ab-2; GM-Tg-bovg-MP1609-Ab-1/ GM-Tg-bovg-MP1609-Ab-2; GM-Tg-equg-MP1609-Ab-1/ GM-Tg-equg-MP1609-Ab-2 |
| Products Name | Anti-SLC35G2 monoclonal antibody |
| Format | mab |
| Target Name | SLC35G2 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-SLC35G2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species S35G2/ SLC35G2/ ™EM22 VLP (virus-like particle) (Products Developing) |
Target information
| Target ID | GM-MP1609 |
| Target Name | SLC35G2 |
| Gene ID | 80723,245020,315957,716881,485675,101095366,511543,100053344 |
| Gene Symbol and Synonyms | Gm519,SLC35G2,™EM22 |
| Uniprot Accession | Q8TBE7,Q5M7A3 |
| Uniprot Entry Name | S35G2_HUMAN,S35G2_RAT |
| Protein Sub-location | Transmembrane Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000168917 |
| Target Classification | N/A |
The target: SLC35G2, gene name: SLC35G2, also named as ™EM22. Located in Golgi apparatus and plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

